Unknown

Dataset Information

0

Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant.

ABSTRACT: Rapid COVID-19 diagnosis in the hospital is essential, although this is complicated by 30%-50% of nose/throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing (NAAT). Furthermore, the D614G spike mutant dominates the pandemic and it is unclear how serological tests designed to detect anti-spike antibodies perform against this variant. We assess the diagnostic accuracy of combined rapid antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease due to either wild-type or the D614G spike mutant SARS-CoV-2. The overall detection rate for COVID-19 is 79.2% (95% CI 57.8-92.9) by rapid NAAT alone. The combined point of care antibody test and rapid NAAT is not affected by D614G and results in very high sensitivity for COVID-19 diagnosis with very high specificity.

SUBMITTER: Mlcochova P 

PROVIDER: S-EPMC7462534 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant.

Mlcochova Petra P   Collier Dami D   Ritchie Allyson A   Assennato Sonny M SM   Hosmillo Myra M   Goel Neha N   Meng Bo B   Chatterjee Krishna K   Mendoza Vivien V   Temperton Nigel N   Kiss Leo L   James Leo C LC   Ciazynska Katarzyna A KA   Xiong Xiaoli X   Briggs John A G JAG   Nathan James A JA   Mescia Federica F   Bergamaschi Laura L   Zhang Hongyi H   Barmpounakis Petros P   Demeris Nikos N   Skells Richard R   Lyons Paul A PA   Bradley John J   Baker Steven S   Allain Jean Pierre JP   Smith Kenneth G C KGC   Bousfield Rachel R   Wilson Michael M   Sparkes Dominic D   Amoroso Glenn G   Gkrania-Klotsas Effrosyni E   Hardwick Susie S   Boyle Adrian A   Goodfellow Ian I   Gupta Ravindra K RK  

Cell reports. Medicine 20200901 6

Rapid COVID-19 diagnosis in the hospital is essential, although this is complicated by 30%-50% of nose/throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing (NAAT). Furthermore, the D614G spike mutant dominates the pandemic and it is unclear how serological tests designed to detect anti-spike antibodies perform against this variant. We assess the diagnostic accuracy of combined rapid antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease due to  ...[more]

Similar Datasets

Unknown SARS-CoV-2 spike protein S:D614G + S:A222V variant
| EMPIAR-10891 | biostudies-other
Unknown Insight into molecular characteristics of SARS-CoV-2 spike protein following D614G point mutation, a molecular dynamics study.
| S-EPMC7832383 | biostudies-literature
Unknown SARS-CoV-2 spike D614G variant confers enhanced replication and transmissibility.
| S-EPMC7605563 | biostudies-literature
Unknown The SARS-CoV-2 Spike variant D614G favors an open conformational state.
| S-EPMC8051874 | biostudies-literature
Unknown Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.
| S-EPMC7337374 | biostudies-literature
Unknown Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.
| S-EPMC7492024 | biostudies-literature
Unknown Emergence and expansion of highly infectious spike protein D614G mutant SARS-CoV-2 in central India.
| S-EPMC8437943 | biostudies-literature
Unknown Spike mutation D614G alters SARS-CoV-2 fitness.
| S-EPMC8158177 | biostudies-literature
Unknown Emergence of Genomic Diversity in the Spike Protein of the "Omicron" Variant.
| S-EPMC10612054 | biostudies-literature
Unknown SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity.
| S-EPMC7693302 | biostudies-literature